GlassScriptPhysician profile
Huiwen Ying
NPI 1093051302
$16,589.30
in general payments reported to CMS, 2019-2025
56 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,051 · 2022: $4,132 · 2023: $3,653 · 2024: $2,770 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,646 · Education: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,646.43 |
| Education | $759.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,875.54 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $1,236.33 | 2021-2025 | Opdivo, Krazati |
| Seagen INC. | $1,209.07 | 2021-2025 | Padcev, Tukysa, Adcetris |
| Lilly USA, LLC | $1,139.76 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $917.46 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $899.90 | 2021-2025 | |
| Janssen Biotech, INC. | $804.01 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Incyte Corporation | $788.84 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $754.18 | 2021-2025 | |
| Daiichi Sankyo INC. | $752.72 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $695.16 | 2021-2025 | Vyloy, Xospata, Xtandi |
| Novartis Pharmaceuticals Corporation | $566.54 | 2021-2025 | |
| Celgene Corporation | $429.10 | 2021-2024 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $416.22 | 2021-2025 | Fruzaqla, Alunbrig |
| Stemline Therapeutics INC. | $370.52 | 2023-2025 | Orserdu |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiwen Ying listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.